Related Experiment Video

Updated: Jul 10, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Age-specific characteristics of the basal insulin-rate for pediatric patients on CSII

C Klinkert1, R Bachran, B Heidtmann

  • 1Pediatric Practice, Herford, Germany. dr.klinkert@t-online.de

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|November 2, 2007
PubMed

Insights

Pediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) show distinct basal insulin needs based on age. Dosages and daily patterns vary significantly across different pediatric age groups.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Diseases
  • Diabetes Management

Background:

  • Type 1 diabetes (T1D) management in children requires precise insulin dosing.
  • Continuous subcutaneous insulin infusion (CSII) offers flexible insulin delivery for T1D.
  • Understanding basal insulin requirements is crucial for optimal glycemic control in pediatric CSII users.

Purpose of the Study:

  • To analyze basal insulin dosage in pediatric patients (0-18 years) with T1D using CSII.
  • To identify age-specific patterns in basal insulin requirements and delivery profiles.

Main Methods:

  • Analysis of a large, prospective German and Austrian diabetes database (DPV).
  • Inclusion of 743 pediatric patients (0-18 years) with T1D on CSII and complete basal rate data.
  • Evaluation of basal rates in relation to age, gender, diabetes duration, body weight, and insulin type, stratified into three age groups (0-6, >6-12, >12-18 years).

Main Results:

  • Significant differences in basal insulin dosage per kilogram of body weight were observed across the three age groups (0.20 IU/kg, 0.34 IU/kg, 0.41 IU/kg respectively; p<0.0001).
  • Basal insulin amounts correlated with body weight, age, and diabetes duration.
  • Distinct circadian distribution profiles of basal rates were identified for each age group.

Conclusions:

  • Pediatric patients with T1D on CSII exhibit age-specific characteristics in both the total amount and circadian distribution of their basal insulin rates.
  • These findings highlight the need for individualized and age-adjusted basal insulin programming in pediatric CSII therapy.
Abstract

More Related Videos

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...